Skip to main content
Toggle navigation
Search
Home
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
N
Nadeem, Omar
Dana-Farber Cancer Institute
(PA-080) Arlocabtagene autoleucel, a GPRC5D-Targeted CAR T-Cell Therapy for Patients With Relapsed/Refractory Multiple Myeloma: Updated Phase 1 Safety and Efficacy Results in Patients With 1–3 Prior Regimens
Location: Room 714A
Omar Nadeem
Neri, Paola
Arnie Charbonneau Cancer Research Institute, University of Calgary
Role of target/tumor as mechanism of resistance to CAR T-cell redirecting therapies
Location: Hall FG
Paola Neri
Nooka, Ajay
Winship Cancer Institute of Emory University
Meet the Experts: Establishing outpatient administration of Bispecifics and immunotherapy
Location: Room 714B
Ajay Nooka
(OA-66) Maintenance Therapy with Belantamab, Pomalidomide and Dexamethasone in High-risk Myeloma Patients: A Phase 2 Study with a Safety Run-in - Interim Analysis
Location: Hall FG
Ajay Nooka
Ntanasis-Stathopoulos, Ioannis
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
(PA-144) Whole Body Magnetic Resonance Imaging (WBMRI) for Response Evaluation in Patients with Multiple Myeloma
Location: Room 714A
Ioannis Ntanasis-Stathopoulos
